News

Battle of the weight loss blockbuster drugs: Zepbound beats Wegovy by nearly 50%
Participants who took tirzepatide — which is sold as Zepbound by Eli Lilly — lost an average of 50 pounds over 72 weeks.
Eli Lilly pulls ahead of Novo in obesity drug gold rush as new players crowd in
Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...
STAT8d
Compounders lose legal battle with FDA over removal of Eli Lilly’s weight loss drug from a shortage list
A new federal ruling means that patients will no longer have access to cheaper versions of Eli Lilly weight loss and diabetes ...
Ozempic maker Novo Nordisk ousts CEO amid plunging share price as rival Eli Lilly gains market share
Novo’s shares have plunged since hitting a record-high in June last year as competition, particularly from Eli Lilly, makes inroads into its market share and as its pipeline of new drugs has ...
Weight-Loss Drugs Aren’t Really About Weight
Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...
Popular injected weight loss medications work better for one sex. Researchers want to know why
In study after study, injected GLP-1 weight loss medications appear to work better on average for women than they do for men.
Adweek on MSN22h
Eli Lilly's Big Task: Become a Loved and Trusted Pharma Brand
A new film from Eli Lilly sounds like a recruitment ad, but it doubles as a brand manifesto to showcase the pharmaceutical ...
Trump calls out weight-loss drugs as target of price-cut push
The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...